Skip to main content
Equibles
ABCL logo

ABCL · AbCellera Biologics Inc. · Metrics

Track ABCL — free

Use ABCL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ABCL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.84 -0.21 (-1.90%)
Rebalance outlook locked
Market Cap
$3.39B
Shares
306.61M

ABCL metrics

66 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$11.05
Market cap
$3.39B

Price action

20 metrics
Price change (1W)
+1.4%
Price change (30D)
+22.5%
Price change (3M)
+115.8%
Price change (6M)
+220.4%
Price change (YTD)
+234.5%
Price change (1Y)
+174.3%
Trailing year
Price change (5Y)
-37.3%
52-week high
$12.50
52-week low
$2.78
Change from 52-week high
-8.5%
Change from 52-week low
+311.5%
Annualized volatility
87.2%
Annualized volatility (3M)
108.8%
Beta
2.7
RSI (14D)
61.2
Price vs SMA 50
+34.6%
Price vs SMA 200
+121.1%
Avg volume (3M)
7.44M
Relative volume
0.3
Average dollar volume
$61.97M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
306.61M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
53.0×
reciprocal yield 1.9%
P / book
3.9
reciprocal yield 25.6%
FCF yield
-3.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-4.7%

Historical valuation

8 metrics
P / E historical average (3Y)
14.7×
reciprocal yield 6.8%
P / E historical average (5Y)
14.7×
reciprocal yield 6.8%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
—
Operating margin
-340.2%
Trailing 12 months
Net margin
-248.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$225.15M
Net income (TTM)
−$164.66M
Trailing 12 months
Diluted EPS (TTM)
$-0.54
FCF margin
-180.8%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$3.22

Growth

11 metrics
Revenue growth YoY
-76.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$66.17M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.4%
Year over year · more shares
Revenue CAGR (3Y)
-46.3%
Revenue CAGR (5Y)
-20.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-18.4%
Return on assets
-12.6%
Debt / equity
—
Current ratio
12.8
EBITDA (TTM)
−$222.24M
Free cash flow (TTM)
−$119.67M
Quick ratio
12.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
—
Total assets
$1.31B
Total debt
$190,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$94.94M
Capital expenditures (TTM)
$24.73M
R&D (TTM)
$197.77M
SG&A (TTM)
—
Stock compensation (TTM)
$51.10M
R&D / revenue
298.9%
Stock compensation / revenue
77.2%

Ownership (13F)

3 metrics
13F filers
149
13F filer change QoQ
+10
Institutional ownership
40.0%

Short interest

3 metrics
Short interest
13.5%
Latest settlement · 3.0 days to cover
Days to cover
3.0d
Short-squeeze score
69 / 100

Insider activity

2 metrics
Net insider buying (90D)
$1.55M
Insider-sentiment score
91 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1703057 CUSIP 00288U106 13F (30d) 85 filings 85 filers Visit website Investor relations